%PDF-1.4
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2015-02-12T11:52:48-06:00
2015-02-12T11:52:49-06:00
2015-02-12T11:52:49-06:00
Adobe InDesign CS6 (Macintosh)
uuid:6c091620-445c-524d-8f22-7c0d98842823
xmp.did:018011740720681188C6B2E00490660B
xmp.id:F87F117407206811822AE69D8BA310CA
proof:pdf
converted
from application/x-indesign to application/pdf
Adobe InDesign CS6 (Macintosh)
/
2015-02-12T11:52:48-06:00
xmp.iid:F77F117407206811822AE69D8BA310CA
xmp.did:018011740720681188C6B2E00490660B
xmp.did:018011740720681188C6B2E00490660B
default
application/pdf
Adobe PDF Library 10.0.1
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 792.0 612.0]/Type/Page>>
endobj
6 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 792.0 612.0]/Type/Page>>
endobj
18 0 obj
<>stream
q
/GS0 gs
/Fm0 Do
Q
BT
/CS0 cs 0 0.552 0.825 scn
/GS0 gs
/T1_0 1 Tf
9 0 0 9 143.1403 42.75 Tm
[(A PDF c)6(op)7(y of this tip sheet is a)8.2(v)4(ailable a)4.1(t )]TJ
0 0.417 0.628 scn
[(h)4(ttp://objec)-12.9(tiv)10.1(ehealth.ca/pdf)8.9(s/obtips)11(.pdf)]TJ
0 0.552 0.825 scn
34.411 0 Td
[(. C)11(or)-4(r)10(ec)-13(tions/additions)11(, email )]TJ
0 0.417 0.628 scn
[(br)5(ady@dr)-4(bouchar)10(d)10(.ca)]TJ
0 0.552 0.825 scn
(.)Tj
0 0 0 scn
/GS1 gs
/T1_1 1 Tf
-0.039 Tw 14 0 0 14 64.8 565.4536 Tm
[(O)-3(bst)5(etric T)23(ips)]TJ
ET
0 0.727 0.947 scn
q 1 0 0 1 36 560.4253 cm
0 0 m
8.425 0 l
8.425 -8.425 l
15.531 -8.425 l
15.531 0 l
24 0 l
24 7.105 l
15.531 7.105 l
15.531 15.575 l
8.425 15.575 l
8.425 7.105 l
0 7.105 l
h
f
Q
/CS0 CS 0 0 0 SCN
0.45 w
q 1 0 0 1 221.9142 336.2001 cm
0 0 m
11.043 0 l
S
Q
q 1 0 0 1 216.1899 282.2001 cm
0 0 m
11.043 0 l
S
Q
q 1 0 0 1 225.0282 239.0001 cm
0 0 m
11.043 0 l
S
Q
q 1 0 0 1 174.6236 185.0001 cm
0 0 m
11.043 0 l
S
Q
BT
0 0 0 scn
/T1_1 1 Tf
0 Tw 10 0 0 10 49 531.5 Tm
[(I)-3(nf)10(ec)-15.9(tions)]TJ
9 0 0 9 49 509.9 Tm
[(UTI in P)9(r)8(egnanc)-14.9(y)]TJ
/T1_0 1 Tf
0 -1.2 TD
[(A)3(mo)14(xicla)8(v 500mg BID x 7/7)]TJ
T*
[(M)-6(acr)10(obid 100mg BID x 3-7/7 \(a)8.3(v)10(oid af)-11(t)6(er 36 w)10.1(eeks\))]TJ
T*
[(C)11(e\036xime 200mg BID x 7/7)]TJ
T*
[(Bac)-13(tr)-4(im DS 1 tab BID x 3/7 )]TJ
/T1_2 1 Tf
[(\(2nd trimest)5.1(er onl)-2.9(y\))]TJ
/T1_1 1 Tf
0 -2.4 TD
[(A)3(sympt)5(oma)8(tic B)-2.9(ac)-16(turia)]TJ
/T1_0 1 Tf
0 -1.2 TD
[(A)3(mo)14(xicillin 500mg PO )41.1(TID x 3-7/7)]TJ
/T1_1 1 Tf
0 -2.4 TD
[(UTI \(N)3(ot pr)8.1(egnan)6(t\))]TJ
/T1_0 1 Tf
0 -1.2 TD
[(A)3(mo)14(xicla)8(v 500mg BID x 7/7)]TJ
T*
[(C)3(ipr)10(o 250mg BID x 3/7 or 500mg daily x 3/7)]TJ
T*
[(Bac)-13(tr)-4(im DS 1 tab BID x 3/7)]TJ
T*
[(M)-6(acr)10(obid 100mg BID x 5/7)]TJ
/T1_1 1 Tf
0 -2.4 TD
[(I)-3(n)6(tr)11(apar)-21(tum F)26.1(e)6(v)15(er)]TJ
/T1_0 1 Tf
0 -1.2 TD
[(C)11(ef)13(o)14(xitin 2g IV sta)4.1(t x 1 \227 no subs)11.1(, then 1g )41.1(TID )]TJ
(OR)Tj
T*
[(A)3(nc)6(ef 2g IV QID + F)17.1(lagyl 500mg IV )41.1(TID)]TJ
T*
[(\(c)6(on)4(tinue 24hrs postpar)-23.8(tum and af)13(ebr)-3.9(ile\))]TJ
/T1_1 1 Tf
0 -2.4 TD
[(Endometritis \(N)3.1(ot pr)8(egnan)6(t\))]TJ
/T1_0 1 Tf
0 -1.2 TD
[(C)3(ipr)10(o 500mg PO BID + F)17.2(lagyl 500mg PO BID)34.1(, )]TJ
(OR)Tj
T*
[(Clindam)13(y)10(cin 900mg IV )41.1(TID + G)-4.9(en)4(tamicin 90mg IV daily)]TJ
/T1_1 1 Tf
0 -2.4 TD
[(PID \(inpa)8(tien)6.1(t tx\))]TJ
/T1_0 1 Tf
0 -1.2 TD
[(C)11(ef)13(o)14(xitin 2g IV QID + D)-3.8(o)13.9(x)-15(y)10(cline 100mg PO BID)34.2(, )]TJ
(OR)Tj
0.165 Tw T*
[(Clindam)13(y)10(cin 900mg IV )40.7(TID + G)-5(en)4.1(tamicin 2mg/kg IV/IM )]TJ
0 Tw T*
[(loading dose then 1.5mg/kg IV )41.2(TID)]TJ
/T1_1 1 Tf
0 -2.4 TD
[(C)3(hlam)19(y)15(dia)]TJ
/T1_0 1 Tf
0.035 Tw 0 -1.2 TD
[(D)-4(o)14(x)-15(y)10(c)-18(y)10(cline 100mg PO BID x 7/7 )]TJ
0 Tw (OR)Tj
0.035 Tw [( A)-14(zithr)10(om)13(y)10(cin 1g PO )]TJ
0 Tw T*
[(x single dose if poor c)6.2(omplianc)6(e e)3(xpec)-12.9(t)6(ed)]TJ
/T1_1 1 Tf
0 -2.4 TD
[(G)-6(onorr)3(hea)]TJ
/T1_0 1 Tf
0.006 Tw 0 -1.2 TD
[(C)11(e\036xime 400mg PO single dose + tr)10(ea)4(t Chlam)13(y)10(dia as w)10(ell )]TJ
0 Tw T*
[(empir)-4(ically)]TJ
/T1_1 1 Tf
26.667 47.15 Td
[(H)3(erp)-3(es)]TJ
/T1_0 1 Tf
T*
[(F)26(irst episode:)]TJ
T*
[(A)12(c)-18(y)10(clo)7(vir 200mg PO 5 times daily x 5/7 OR)]TJ
T*
[(F)45(amiciclo)7(vir 250mg PO )41.1(TID x 5/7 OR)]TJ
T*
[(V)33(alac)-18(y)10(clo)7(vir 1000mg PO BID x 10/7)]TJ
0.112 Tw 0 -2.4 TD
[(I)-10(f sev)10(er)10.1(e: A)12(c)-18(y)10(clo)7(vir 5mg/kg IV infused o)7(v)10(er 60min ev)10(er)-25(y )]TJ
0 Tw 0 -1.2 TD
(8 hours)Tj
0 -2.4 TD
[(R)-4(ecur)-4(r)10(en)4(t:)]TJ
0 -1.2 TD
[(A)12(c)-18(y)10(clo)7(vir 200mg PO 5 times daily x 5/7 OR)]TJ
T*
[(F)45(amiciclo)7(vir 125mg PO BID x 5/7 OR)]TJ
T*
[(V)33(alac)-18(y)10(clo)7(vir 500mg PO BID x 3/7)]TJ
0 -2.4 TD
[(Suppr)10(essiv)10.1(e ther)5(ap)7(y \(not pr)10.1(eg)6(nan)4(t\):)]TJ
0 -1.2 TD
[(A)12(c)-18(y)10(clo)7(vir 400mg PO BID)34.2(, OR)]TJ
T*
[(F)45(amiciclo)7(vir 250mg PO BID)34.2(, OR)]TJ
-0.034 Tw T*
[(V)33(alac)-18(y)10(clo)7(vir 500mg PO daily \(1000mg if >9 episodes/y)10(ear\))]TJ
0 Tw 0 -2.4 TD
[(Suppr)10(essiv)10.1(e ther)5(ap)7(y)-24(:)]TJ
0 -1.2 TD
[(A)12(c)-18(y)10(clo)7(vir 400mg PO QID)34.1(, OR)]TJ
T*
[(F)45(amiciclo)7(vir 250mg PO )41.1(TID)34(, OR)]TJ
T*
[(V)33(alac)-18(y)10(clo)7(vir 500mg PO BID)]TJ
/T1_1 1 Tf
-0.037 Tw 0 -2.4 TD
[(B)-3(ac)-16(t)5(erial V)42(aginosis)]TJ
/T1_0 1 Tf
0 Tw 0 -1.2 TD
[(F)17(lagyl 500mg PO BID x 10-14/7 OR)]TJ
T*
[(M)-6(etr)10(onidaz)7.1(ole G)-5(el 0.75%, one applica)4.2(tion PV daily x 10/7)]TJ
/T1_1 1 Tf
0 -2.4 TD
[(T)54(rich)]TJ
/T1_0 1 Tf
0 -1.2 TD
[(F)17(lagyl 500mg PO BID x 7/7 OR 2g PO single dose)]TJ
/T1_1 1 Tf
0 -2.4 TD
[(C)10(andida)]TJ
/T1_0 1 Tf
0 -1.2 TD
[(F)17(luc)6(onaz)7(ole 150mg PO single dose)]TJ
T*
[(I)-10(f r)10(ecur)-4(r)10.1(en)4(t)3(, r)10(epea)4(t Q3D f)13.1(or 3 doses)]TJ
/T1_1 1 Tf
0 -2.4 TD
[(W)42(ound inf)10.1(ec)-16(tions)]TJ
/T1_0 1 Tf
0 -1.2 TD
[(Ke\037e)3(x 500mg PO QID OR)]TJ
T*
[(Clindam)13(y)10(cin 300mg PO )41.1(TID)]TJ
/T1_1 1 Tf
10 0 0 10 529 555.5 Tm
[(O)-13(ther M)-2.9(eds)]TJ
9 0 0 9 529 533.9 Tm
[(GERD / Re\037ux \(saf)10.1(e in pr)8(egnanc)-15(y\))]TJ
/T1_0 1 Tf
0 -1.2 TD
[(R)-12(anitidine 150mg PO BID)]TJ
/T1_1 1 Tf
0 -2.4 TD
[(P)9(r)8(e)-30(-)-16(op P)9(r)8(oph)19.1(ylaxis)]TJ
/T1_0 1 Tf
0 -1.2 TD
[(A)3(nc)6(ef 2g IV on call t)6.1(o OR)]TJ
T*
[(R)-12(anitidine 150mg PO/IV)]TJ
T*
[(M)-6(ax)15(er)5(an 10mg PO/IV)]TJ
T*
[(S)-6(odium citr)5.1(a)3.9(t)6.1(e 30mg PO)]TJ
0 -2.4 TD
[(O)-17(thers:)]TJ
0 -1.2 TD
[(I)-10(ndomethacin supp)24.1(. 100mg PR BID)]TJ
T*
[(F)31(er)-4(r)10(ous gluc)6.1(ona)4(t)6(e 300mg BID \(if Hgb < 100\))]TJ
T*
[(F)31(olic acid 5mg PO daily \(Hgb < 80\))]TJ
0.525 0.533 0.543 scn
/GS0 gs
/T1_3 1 Tf
-51.533 16.812 Td
[(F)28(or )36(W)38(ork)-12.9(ing on Labour & Deliv)13.2(er)-22(y)]TJ
ET
endstream
endobj
17 0 obj
<>/ExtGState<>>>/Subtype/Form>>stream
/CS0 CS 0.884 0.956 0.992 SCN
19 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 36 45.5 cm
0 0 m
720 0 l
S
Q
endstream
endobj
9 0 obj
<>
endobj
8 0 obj
[/ICCBased 19 0 R]
endobj
19 0 obj
<>stream
HyTSwoɞc
[5laQIBHADED2mtFOE.c}088GNg9w߽ '0 ֠Jb
2y.-;!KZ ^i"L0-
@8(r;q7Ly&Qq4j|9
V)gB0iW8#8wթ8_٥ʨQQj@&A)/g>'K t;\
ӥ$պFZUn(4T%)뫔0C&Zi8bxEB;Pӓ̹Aom?W=
x- [ 0}y)7ta>jT7@tܛ`q2ʀ&6ZLĄ?_yxg)˔zçLU*uSkSeO4?c. R
߁-25 S>ӣVd`rn~Y&+`;A4 A9 =-tl`;~p Gp| [`L`< "AYA+Cb(R, *T2B-
ꇆnQt}MA0alSx k&^>0|>_',G!"F$H:R!zFQd?r9\A&GrQhE]a4zBgE#H *B=0HIpp0MxJ$D1D, VĭKĻYdE"EI2EBGt4MzNr!YK ?%_(0J:EAiQ(()ӔWT6U@P+!~mDeԴ!hӦh/']B/ҏӿ?a0nhF!X8܌kc&5S6lIa2cKMA!E#ƒdV(kel
}}Cq9
N')].uJr
wG xR^[oƜchg`>b$*~ :Eb~,m,-ݖ,Y¬*6X[ݱF=3뭷Y~dó tizf6~`{v.Ng#{}}jc1X6fm;'_9 r:8q:˜O:ϸ8uJqnv=MmR 4
n3ܣkGݯz=[==<=GTB(/S,]6*-W:#7*e^YDY}UjAyT`#D="b{ų+ʯ:!kJ4Gmt}uC%K7YVfFY.=b?SƕƩȺy
چk5%4m7lqlioZlG+Zzmzy]?uuw|"űNwW&e֥ﺱ*|j5kyݭǯg^ykEklD_p߶7Dmo꿻1ml{Mś
nLl<9O [$h՛BdҞ@iءG&vVǥ8nRĩ7u\ЭD- u`ֲK³8%yhYѹJº;.!
zpg_XQKFAǿ=ȼ:ɹ8ʷ6˶5̵5͵6ζ7ϸ9к<Ѿ?DINU\dlvۀ܊ݖޢ)߯6DScs
2F[p(@Xr4Pm8Ww)Km
endstream
endobj
12 0 obj
<>
endobj
13 0 obj
<>
endobj
15 0 obj
<>
endobj
14 0 obj
<>
endobj
29 0 obj
<>
endobj
30 0 obj
<>stream
HdN#G=ObusK\`f2̂OJ>nw7hSާN/}z|:N˷~,_Wf;grus3]~~1/_OWuriߧt{;~~xy>ί?|>c?>^i>7`/a_v۫xf/Nڟ9!ol<4<2:6#ofofofofollFyK*[Uvd^9r$Gy